

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

Cytiva: AKTA pure 25 L chromatography system

RRID:SCR_023461

Type: Tool

Proper Citation

Cytiva: AKTA pure 25 L chromatography system (RRID:SCR_023461)

Resource Information

URL: <https://www.cytivalifesciences.com/en/us/shop/chromatography/chromatography-systems/akta-pure-p-05844>

Proper Citation: Cytiva: AKTA pure 25 L chromatography system (RRID:SCR_023461)

Description: Chromatography system for purification in research applications. Allows for customization due to its modular design with flow rate. Available with flow rate of up to 25 mL/min or flow rate of up to 150 mL/min. Offers more than 20 hardware options for custom system, including new UV monitor. Includes Air sensor L9;CELL 2 U KPL;Conductivity monitor C9n Cpl;Injection valve V9-Inj;Instrument control unit, I9, Äkta pure; Mixer M9;Pressure monitor R9-2 with pump restrictor; Pump P9 Cpl 2x; UV Monitor U9-L Cpl;Fraction collector F9-R, Cytiva, CAT# 29011362;Superdex 200 increase 10/300 GL, Cytiva, CAT# 28-9909-44.

Synonyms: ÄKTA pure 25 L chromatography system, ÄKTA pure™ 25 L chromatography system, AKTA pure 25 L chromatography system

Resource Type: instrument resource

Keywords: Cytiva, AKTA, 25 L, chromatography system, instrument, equipment, USEDit

Availability: Restricted

Resource Name: Cytiva: AKTA pure 25 L chromatography system

Resource ID: SCR_023461

Record Creation Time: 20230412T050205+0000

Record Last Update: 20260919T195534+0000

Ratings and Alerts

No rating or validation information has been found for Cytiva: AKTA pure 25 L chromatography system.

No alerts have been found for Cytiva: AKTA pure 25 L chromatography system.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Nørregaard KS, et al. (2026) The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. *Molecular cancer therapeutics*, 25(1), 140.

Hofstetter M, et al. (2026) Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia. *Cancer research communications*, 6(4), 946.

Hammoudi A, et al. (2026) Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. *EBioMedicine*, 127, 106269.

Lueck J, et al. (2026) Dimerization-dependent gel-like condensation with dsDNA underpins the activation of human cGAS. *Cell reports*, 45(2), 116920.

Ahsan FM, et al. (2026) Reductive death is averted by a conserved de novo lipogenic switch. *Molecular cell*, 86(13), 2539.

Black JJ, et al. (2026) The *Legionella pneumophila* effector SidL is an adenylyltransferase that modifies the glycolytic intermediate 3-phosphoglycerate. *Molecular cell*.

Lal S, et al. (2025) Nanoparticle-formulated mRNA encoding engineered multivalent SIRP ?-Fc fusion proteins shows robust anti-cancer activity in preclinical models. *Molecular therapy. Nucleic acids*, 36(2), 102550.

Martinez P, et al. (2024) Protocol for the isolation and proteomic analysis of pathological tau-seeds. *STAR protocols*, 5(3), 103185.

Zhao GX, et al. (2024) Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection. *Cell reports. Medicine*, 5(5), 101573.

Sass MI, et al. (2024) Protocol to study CCT-mediated folding of G?5 by single-particle cryo-EM. *STAR protocols*, 5(2), 103116.

Pandey A, et al. (2024) Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I complex Demonstrates the Antitumor Efficacy of

Hapten-Based Strategies. Cancer research.

Baron N, et al. (2024) LeishIF4E2 is a cap-binding protein that plays a role in Leishmania cell cycle progression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(1), e23367.

Ray R, et al. (2024) Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. Immunity, 57(5), 1141.

Altay MF, et al. (2023) Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. NPJ Parkinson's disease, 9(1), 161.

Sulbaran G, et al. (2022) Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell reports. Medicine, 3(2), 100528.